B. Riley Decreases Earnings Estimates for ClearPoint Neuro

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – B. Riley cut their Q2 2025 earnings per share (EPS) estimates for shares of ClearPoint Neuro in a report issued on Tuesday, May 13th. B. Riley analyst A. Schock now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous estimate of ($0.14). B. Riley has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.65) EPS.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million.

A number of other research analysts also recently weighed in on CLPT. Lake Street Capital increased their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. Stifel Nicolaus boosted their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st.

ClearPoint Neuro Trading Up 3.9%

Shares of CLPT opened at $12.92 on Friday. The firm has a fifty day simple moving average of $12.86 and a two-hundred day simple moving average of $14.22. The firm has a market cap of $361.62 million, a PE ratio of -18.72 and a beta of 1.03. ClearPoint Neuro has a 1-year low of $5.11 and a 1-year high of $19.22.

Institutional Trading of ClearPoint Neuro

A number of hedge funds and other institutional investors have recently bought and sold shares of CLPT. R Squared Ltd bought a new position in shares of ClearPoint Neuro during the 4th quarter valued at approximately $32,000. Deutsche Bank AG bought a new position in shares of ClearPoint Neuro in the first quarter worth approximately $63,000. Barclays PLC raised its position in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after purchasing an additional 1,109 shares during the period. AlphaQuest LLC purchased a new position in shares of ClearPoint Neuro during the 4th quarter valued at $80,000. Finally, Tower Research Capital LLC TRC bought a new position in ClearPoint Neuro in the 4th quarter worth $93,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.